The Promise and Politics of Creating mRNA Vaccines in Cancer

In June, Moderna and Merck reported clinical trial follow-up results showing that their combination mRNA cancer vaccine and immunotherapy reduced the risk of melanoma recurrence in high-risk patients by nearly half over 5 years.¹